<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='54'><Row><Action id="4805">IL-17 release inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1615">Neuroprotectant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="4805">IL-17 release inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="4805">IL-17 release inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="4935">IL-6 release inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1615">Neuroprotectant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="4935">IL-6 release inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="651">Cancer</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="230">Neoplasm</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="4935">IL-6 release inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="18604">MYC gene inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2014-02-12 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1615">Neuroprotectant</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="2953">Anti-inflammatory</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="72072">BET inhibitors (cancer/autoimmune disorders), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="291">Rheumatoid arthritis</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2013-06-03 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="185">Immune disorder</TherapyArea></Row><Row><Action id="1545">Anticancer</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1731">Acute myelogenous leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="1589">Apoptosis stimulator</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1733">Chronic leukemia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="S">Suspended</Status><StatusDate>2014-10-14 00:00:00</StatusDate><StatusSortCode>5</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="34558">Bromodomain containing protein inhibitor</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1084523">Zenith Epigenetics Corp</Company><Country id="CA">Canada</Country><Drug id="84390">BET inhibitors (cancer), Zenith Epigenetics</Drug><EntityType>Chemical</EntityType><HighestDevStatus id="S">Suspended</HighestDevStatus><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="1828">Multiple myeloma</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-10-14 00:00:00</LatestChange><ParentCompany id="1084523">Zenith Epigenetics Corp</ParentCompany><Status id="C1">Phase 1 Clinical</Status><StatusDate>2014-10-02 00:00:00</StatusDate><StatusSortCode>8</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row></Rowset>